NCT03561779已完成3 期
A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Study to Evaluated the Safety and Efficacy of Intraarticular Hyalurinic Acid(YYD302) for Osteoarthritis of the Knee After 12 Weeks of Treatment and Retreatment
Yooyoung Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 184 人开始时间: 2018年2月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline
研究概览
简要总结
This is a randomized, double-blind, active-controlled, multi-center, phase 3 study to evaluate the safety and efficacy of intraarticular hyaluronic acid(YYD302) for osteoarthritis of the knee after 12 weeks of treatment and retreatment
详细描述
First Injection: A multicenter, active-controlled, randomized, evaluator and subject bllinded, parallel, phase 3 study Re-Injection: A multicenter, active-controlled, randomized, parallel
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •[Visit 1, 2 Inclusion Criteria]
- •Males or Females 40 years and older
- •According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.
- •Over 50 years of age 2) Less than 30 minutes of morning stiffness 3) Crepitus on active motion 4) 4 bony tenderness 5) Bony enlargement 6) Nopalpable warmth of synvium
- •Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.
- •By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm
- •Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.
- •Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.)
- •Patient who agrees to participate in this clinical trial by themselves.
- •[Visit 6, 7 Inclusion criteria]
- •According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.
- •Over 50 years of age
- •Less than 30 minutes of morning stiffness
- •Crepitus on active motion
- •4 bony tenderness
- •Bony enlargement
- •Nopalpable warmth of synvium
- •At Re-screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.
- •Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.)
- •Patient who are confirmed for Responder by efficacy at visit 5.
排除标准
- •Someone who has BMI≥32kg/m² at the screening visit.
- •Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually.
- •Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period.
- •Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine).
- •Patient who has rheumarthritis or other inflammatory metabolic arthritis.
- •Patients having serious gastrointestinal, liver, renal, heart disease.
- •When the inflammatory disease is occurred on joint area to patient like septic arthritis.
- •Patients having skin ailment at the injecting site of the joint region.
- •Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease.
- •Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation.
- •Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain.
- •Patients who diagnosed clear interval disappearance at the knee joint by X-ray.
- •Patients who were administrated below drugs before baseline visit. 1) Patients who were injected HA at the target knee joint or other parts of knee joint in recent 9 months.
- •Patients who were injected steroids into the intra-articular knee joint in recent 3 months 3) Patients who were administrated steroids systemically by the oral medication (But, except inhalation) 4) Patients who were administerated Osteoarthritis nutrition such as glucosamine/chondroichin sulfate or physical therapy or herbal remedy(acupuncture, yellowish swelling, moxa cautery) for the purpose of pain relief in recent 2 weeks 5) Patients who have administerated steroid/No-steriod NSAIDs or other pain relief drugs (patch or other external medicine) in recents 2 weeks except Acetaminophen or below 300mg/day of Asprin
- •Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test.
- •Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal.
- •Patients who have an operation history about target knee joint.
- •Patients who do the height weight aerobic exercise or anaerobic exercise.
- •Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin)
- •Patients who have hypersensitivity history about Investigational Product.
- •In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product.
- •The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc.
- •Pregnant and lactating women
- •Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail.
- •Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision.
- •Exclusion criteria for Re-injection is except for 13-1) Re-injection date is followed by visit 7.
研究组 & 干预措施
YYD302
Experimental
YYD302 (2ml)
干预措施: YYD302 2ml (Drug)
结局指标
主要结局
Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline
时间窗: Change of the week 12 from baseline
Weight-bearing pain(100mm-VAS) assessed by the subject
次要结局
- Rate of change of the KOOS scales on the 2, 4, 12 weeks after administration in comparison with baseline(Change of the week 2, 4, 12 from baseline)
- Rate of change of the Motion pain (100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline(Change of the week 2, 4, 12 from baseline)
- Rate of change of the Weight-bearing pain(100mm-VAS) on 2, 4 weeks after administration in comparison with baseline(Change of the week 2, 4 from baseline)
- Rate of change of the rest pain(100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline(Change of the week 2, 4, 12 from baseline)
- Change of the swelling in the knee joint from baseline to 2, 4, 12 weeks after administration(Change of the week 2, 4, 12 from baseline)
- Variation of the Range Of Motion(ROM) in the knee joint on 2, 4, 12 weeks after administration with baseline(Change of the week 2, 4, 12 from baseline)
- Responder rate of the Weight-bearing pain on 12 weeks in comparison with baseline(Change of the week 12 from baseline)
- Responder rate of the OMERACT-OARSI on 12 weeks in comparison with baseline(Change of the week 12 from baseline)
- The efficacy of secondary outcome 1~11 after baseline compared with 2, 4, 12, 24, 36 weeks in Re-injection subjects(Change of the week 2, 4, 12, 24, 36 from baseline)
- Patient global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline(Change of the week 2, 4, 12 from baseline)
- Investigator global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline(Change of the week 2, 4, 12 from baseline)
- Change of the tenderness on pressure in the knee joint from baseline to 2, 4, 12 weeks after administration(Change of the week 2, 4, 12 from baseline)
- Use of rescue medication count and the total amount on each visit after injection(Change of the each visit(2, 4, 12, 24, 36 weeks) after injection)
- The efficacy of secondary outcome 1~11 after 12 weeks(36weeks) compared with the Re-injection(24weeks) in re-injection subjects(Change of the week 12 (36 weeks) after Re-injection(24weeks))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis PatientsRifampin-Resistant Pulmonary TuberculosisTuberculosis, Multidrug-Resistant (MDR-TB)NCT05824871Shanghai Jiatan Pharmatech Co., Ltd450
尚未招募
3 期
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of BoneGiant Cell Tumor of BoneNCT05813665Shanghai JMT-Bio Inc.146
已完成
3 期
Aripiprazole IM Depot in the Acute Treatment of Adults With SchizophreniaSchizophreniaNCT03172871Otsuka Beijing Research Institute436
已完成
3 期
Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic BronchitisEvaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic BronchitisNCT03489837Hyundai Pharm272
已完成
3 期
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and HyperlipidemiaHypertensionHyperlipidemiaNCT03067688Yuhan Corporation202